Supernus Pharmaceuticals, Inc. (SUPN) News
Follow Supernus Pharmaceuticals, Inc. (SUPN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
SUPN: Nasdaq trading halt continues — reason not given (3:58 AM ET)
Nasdaq kept trading halted in SUPN (reason not given) at 3:58 AM ET.
EQUITY | Nov 02, 2026, 08:58 AM UTC
M
Supernus Pharmaceuticals reports quarterly results
Supernus Pharmaceuticals reported results for the quarter ended September 30.
EQUITY | Oct 29, 2026, 10:32 PM UTC
L
Supernus Pharmaceuticals Reports Third-Quarter 2026 Revenue of $226.77 Million
Supernus Pharmaceuticals reported third-quarter 2026 revenue of $226.77 million, up 18% from a year earlier, net income of $20.91 million versus a $45.12 million loss, and diluted EPS of $0.35 versus a loss of $0.8 per s
EARNINGS | Oct 29, 2026, 08:24 PM UTC
M
Supernus Reports Q3 Revenue of $226.8 Million, Up 18%
Supernus reported third-quarter 2026 net earnings of $20.9 million and operating income of $21.2 million, versus an operating loss a year earlier. It also raised its standalone full-year revenue and operating ea…
EQUITY | Oct 29, 2026, 08:21 PM UTC
M
Supernus Pharmaceuticals Q3 Revenue Rises 18% on CNS Growth
EQUITY | Oct 29, 2026, 08:20 PM UTC
L
Huron Consulting Group to Join S&P SmallCap 600
Huron Consulting Group will replace Supern… in the S&P SmallCap 600; the provided body is truncated.
EQUITY | Oct 28, 2026, 09:43 PM UTC
H
SUPN: Strong CNS portfolio growth and a strategic merger position the company for accelerated innovation
The company is advancing a CNS-focused portfolio with strong growth in ADHD and Parkinson's products, a successful postpartum depression launch, and a promising pipeline. The planned Indivior merger aims to accelerate di
MNA | Sep 09, 2026, 08:13 PM UTC
H
SUPN: Strong CNS portfolio growth, innovative pipeline, and Indivior merger set to drive future expansion
The company is advancing a CNS-focused portfolio with strong growth in ADHD and Parkinson's products, overcoming supply challenges and expanding through strategic M&A. The pipeline features innovative treatments for depr
MNA | Sep 09, 2026, 07:39 PM UTC
L
SUPN - Supernus Pharmaceuticals to Participate in September Investor Conferences
SUPN - Supernus Pharmaceuticals to Participate in September Investor Conferences
EQUITY | Sep 02, 2026, 08:30 PM UTC
L
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength o
EARNINGS | Aug 04, 2026, 10:04 AM UTC
L
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) and Indivior Pharmaceuticals Inc. (NASDAQ: INDV ) on Monday agreed to unite through a tax-free all-stock merger of equals, forming a central nervous system (CNS) biopharmace
EARNINGS | Aug 03, 2026, 02:44 PM UTC
H
Supernus, Indivior Merge
Supernus and Indivior merge to create CNS biopharmaceutical leader
MNA | Aug 03, 2026, 12:26 PM UTC
H
Indivior Buys Supernus
Indivior acquires Supernus in stock deal
MNA | Aug 03, 2026, 10:35 AM UTC
L
SUPN - Supernus Announces Second Quarter 2026 Financial Results
SUPN - Supernus Announces Second Quarter 2026 Financial Results
EARNINGS | Aug 03, 2026, 10:35 AM UTC
L
SUPN +12%, INDV +2% premarket after M&A headlines
SUPN +12%, INDV +2% premarket after M&A headlines
MNA | Aug 03, 2026, 10:34 AM UTC
H
SUPN, INDV Agree Merger
SUPN and INDV agree to merge
MNA | Aug 03, 2026, 10:33 AM UTC
H
Supernus Pharmaceuticals Merges With Indivior
Supernus stockholders get Indivior shares
MNA | Aug 03, 2026, 10:31 AM UTC
H
SUPN INDV Supernus Pharmaceuticals and Indivior Pharmaceuticals to merge, creating a diversified Cns biopharmaceutical leader with significa
SUPN INDV Supernus Pharmaceuticals and Indivior Pharmaceuticals to merge, creating a diversified Cns biopharmaceutical leader with significant scale Supernus Pharmaceuticals Inc - combined entity to be named Supernus, In
MNA | Aug 03, 2026, 10:31 AM UTC
H
Supernus, Indivior to Merge
Supernus and Indivior merge to create CNS biopharmaceutical leader
MNA | Aug 03, 2026, 10:30 AM UTC